{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:16Z","timestamp":1793047036142,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaut.2026.103617","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:34:31Z","timestamp":1788348871000},"page":"103617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Difficult-to-treat systemic lupus erythematosus: from refractory disease to a multidimensional clinical trajectory"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-3632","authenticated-orcid":false,"given":"Saviana","family":"Gandolfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Whittal","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-1264","authenticated-orcid":false,"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jaut.2026.103617_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jaut.2026.103617_bib2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41573-025-01242-0","article-title":"Advances in the treatment of systemic lupus erythematosus","volume":"24","author":"Scherlinger","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jaut.2026.103617_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.171454","article-title":"Persistent disease activity remains a burden for patients with systemic lupus erythematosus","volume":"46","author":"Peschken","year":"2019","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.10.002","article-title":"EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis","volume":"85","author":"Marzo-Ortega","year":"2026","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2026.103617_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101938","article-title":"Clinical patterns of disease: from early systemic lupus erythematosus to late-onset disease","volume":"37","author":"Piga","year":"2023","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0961203318817132","article-title":"Disease course patterns in systemic lupus erythematosus","volume":"28","author":"Tselios","year":"2019","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaut.2026.103617_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/kez516","article-title":"Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort","volume":"59","author":"Segura","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2011.04.027","article-title":"Refractory disease in systemic lupus erythematosus","volume":"10","author":"Campar","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-025-03622-8","article-title":"Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort","volume":"27","author":"Kandane-Rathnayake","year":"2025","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl5","key":"10.1016\/j.jaut.2026.103617_bib11","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000542","article-title":"Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2026.103617_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/rheumatology\/kead166","article-title":"Which extra-renal flare is \u2018difficult to treat\u2019 in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches","volume":"63","author":"Maffi","year":"2024","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3899\/jrheum.2024-0053","article-title":"Anifrolumab in refractory systemic lupus erythematosus: a real-world, multicenter study","volume":"51","author":"Tani","year":"2024","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103617_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00296-025-05879-3","article-title":"Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of \u2265 10 years: a real-world evidence study","volume":"45","author":"Staveri","year":"2025","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005400","article-title":"Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?","volume":"11","author":"Parodis","year":"2025","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2026.103617_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.43452","article-title":"2025 American college of rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus","volume":"78","author":"Sammaritano","year":"2026","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"Supplement_5","key":"10.1016\/j.jaut.2026.103617_bib21","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology"},{"issue":"14","key":"10.1016\/j.jaut.2026.103617_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1177\/09612033221129776","article-title":"Residual disease activity and treatment intensification in systemic lupus erythematosus: a cross-sectional study to quantify the need for new therapies","volume":"31","author":"Gioti","year":"2022","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/acr.23794","article-title":"A novel system to categorize the symptoms of systemic lupus erythematosus","volume":"71","author":"Pisetsky","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/09612033241242692","article-title":"Factors associated with non-adherence to medications in systemic lupus erythematosus: results from a Swedish survey","volume":"33","author":"Emamikia","year":"2024","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/acr.23191","article-title":"Medication nonadherence in systemic lupus erythematosus: a systematic review","volume":"69","author":"Mehat","year":"2017","journal-title":"Arthritis Care Res."},{"issue":"7","key":"10.1016\/j.jaut.2026.103617_bib26","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/jcm11071857","article-title":"How can we enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study","volume":"11","author":"Emamikia","year":"2022","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2026.103617_bib28","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.3390\/jcm12093348","article-title":"Treat-to-Target in systemic lupus erythematosus: reality or pipe dream","volume":"12","author":"Zucchi","year":"2023","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.jaut.2026.103617_bib29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/ard-2023-225369","article-title":"Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study","volume":"83","author":"Katsumata","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000237","article-title":"Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort","volume":"5","author":"Davidson","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib31","first-page":"2023","article-title":"Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus","volume":"40","author":"Costenbader","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/RHU.0000000000001899","article-title":"Health care utilization in systemic lupus erythematosus in the community: the lupus midwest network","volume":"29","author":"Chevet","year":"2023","journal-title":"J. Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103617_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"Van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"8","key":"10.1016\/j.jaut.2026.103617_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103374","article-title":"Organ damage in systemic lupus erythematosus patients: a multifactorial phenomenon","volume":"22","author":"Ceccarelli","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.jaut.2026.103617_bib36","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2026.103617_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/jcm10020243","article-title":"The main challenges in systemic lupus erythematosus: where do we stand?","volume":"10","author":"Piga","year":"2021","journal-title":"JCM"},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.jaut.2026.103617_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006061","article-title":"Poor health-related quality of life despite lupus low disease activity state or definitions of remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting","volume":"11","author":"Parodis","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2026.103617_bib40","article-title":"Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.22881","article-title":"Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus","volume":"57","author":"McElhone","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2011.12.005","article-title":"Disease-specific patient reported outcome tools for systemic lupus erythematosus","volume":"42","author":"Jolly","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.jaut.2026.103617_bib43","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/0961203317739128","article-title":"Validation of the LupusPRO version 1.8: an update to a disease-specific patient-reported outcome tool for systemic lupus erythematosus","volume":"27","author":"Azizoddin","year":"2018","journal-title":"Lupus"},{"issue":"Supplement_5","key":"10.1016\/j.jaut.2026.103617_bib44","doi-asserted-by":"crossref","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaut.2026.103617_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103721","article-title":"Risk factors associated with thrombocytopenia in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"24","author":"Yang","year":"2025","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103617_bib47","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2665-9913(25)00063-3","article-title":"ERN ReCONNET\u2013SLICC\u2013SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations","volume":"7","author":"Arnaud","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103617_bib48","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/rheumatology\/keae227","article-title":"Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide","volume":"63","author":"Mosca","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2026.103617_bib49","doi-asserted-by":"crossref","DOI":"10.2174\/0115733971421580251203103143","article-title":"Recent advances in multi-omics of systemic lupus erythematosus","author":"Wang","year":"2026","journal-title":"Curr Rheumatol Rev"},{"issue":"5","key":"10.1016\/j.jaut.2026.103617_bib50","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.42389","article-title":"A flare risk index informed by select immune mediators in systemic lupus erythematosus","volume":"75","author":"Munroe","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103617_bib51","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2026.103617_bib52","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/art.42248","article-title":"Longitudinal immune cell profiling in patients with early systemic lupus erythematosus","volume":"74","author":"Sasaki","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13075-022-02791-0","article-title":"Mobile health apps for systemic lupus erythematosus and lupus nephritis: a critical appraisal","volume":"24","author":"Ramasamy","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.jaut.2026.103617_bib54","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103617_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103025","article-title":"Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus","volume":"136","author":"Lindblom","year":"2023","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.jaut.2026.103617_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc.2017.5","article-title":"Tissue-specific tumorigenesis: context matters","volume":"17","author":"Schneider","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.jaut.2026.103617_bib58","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/ijms27094026","article-title":"Redefining difficult-to-treat systemic lupus erythematosus: biomarkers of molecular refractoriness beyond clinical failure","volume":"27","author":"Matusiewicz","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jaut.2026.103617_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001526","article-title":"Validation of eight endotypes of lupus based on whole-blood RNA profiles","volume":"12","author":"Hubbard","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ard.2025.01.044","article-title":"Responsiveness of systemic lupus erythematosus subjects to iberdomide based on molecular endotypes","volume":"84","author":"Bachali","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2026.103617_bib61","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","article-title":"Interferon and B-cell signatures inform precision medicine in lupus nephritis","volume":"9","author":"Parodis","year":"2024","journal-title":"Kidney Int. Rep."},{"issue":"7","key":"10.1016\/j.jaut.2026.103617_bib62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard-2023-224795","article-title":"Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a Pan-European systemic lupus erythematosus cohort","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2026.103617_bib63","article-title":"Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE","volume":"5","author":"G\u00f3mez-Ba\u00f1uelos","year":"2024","journal-title":"Cell Rep. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:05:46Z","timestamp":1793045146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":63,"alternative-id":["S0896841126000958"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103617","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Difficult-to-treat systemic lupus erythematosus: from refractory disease to a multidimensional clinical trajectory","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103617"}}